Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENVB Enveric Biosciences

Pre-Market Trading 05-10 08:42:08 EDT

0.9200

-0.0600

-6.12%

盘前0.8799

-0.0401-4.36%

08:40 EDT

High0.9900	Low0.9010	Vol948.84K
Open0.9044	D1 Closing0.9800	Amplitude9.08%
Mkt Cap6.71M	Tradable Cap6.60M	Total Shares7.29M
T/O884.55K	T/O Rate13.23%	Tradable Shares7.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ENVB","market":"US","secType":"STK","nameCN":"Enveric Biosciences","latestPrice":0.92,"timestamp":1715284800000,"preClose":0.98,"halted":0,"volume":948843,"hourTrading":{"tag":"盘前","latestPrice":0.8799,"preClose":0.92,"latestTime":"08:40 EDT","volume":30340,"amount":26410.0161104,"timestamp":1715344852581},"delay":0,"floatShares":7174586,"shares":7294005,"eps":-8.086267,"marketStatus":"Pre-Market Trading","change":-0.06,"latestTime":"05-10 08:42:08 EDT","open":0.9044,"high":0.99,"low":0.901,"amount":884552.6908052099,"amplitude":0.090816,"askPrice":0.8775,"askSize":50,"bidPrice":0.86,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-8.086267,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1715347800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.92,"preHourTrading":{"tag":"盘前","latestPrice":0.8799,"preClose":0.92,"latestTime":"08:40 EDT","volume":30340,"amount":26410.0161104,"timestamp":1715344852581},"postHourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.92,"latestTime":"19:59 EDT","volume":89818,"amount":79666.9037,"timestamp":1715299197051},"volumeRatio":0.24113804842878},"requestUrl":"/m/hq/s/ENVB/wiki","defaultTab":"wiki","newsList":[{"id":"2434830072","title":"Enveric Biosciences Inc    expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434830072","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434830072?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:00","pubTimestamp":1715342443,"startTime":"0","endTime":"0","summary":"* Enveric Biosciences Inc     is expected to report resultson May 13 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate for Enveric Biosciences Inc is for a loss of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433442477","title":"BRIEF-Enveric Biosciences Announces Signing Of Non-Binding Term Sheet With Undisclosed Licensee For Exclusive License To Patented Methods Of Treating Breast And Other Cancers Using Cannabinoids","url":"https://stock-news.laohu8.com/highlight/detail?id=2433442477","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433442477?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:22","pubTimestamp":1715167320,"startTime":"0","endTime":"0","summary":"May 8  - Enveric Biosciences Inc   :   * ENVERIC BIOSCIENCES ANNOUNCES SIGNING OF NON-BINDING TERM SHEET WITH UNDISCLOSED LICENSEE FOR EXCLUSIVE LICENSE TO PATENTED METHODS OF TREATING BREAST AND OTHER CANCERS USING CANNABINOIDS   * ENVERIC BIOSCIENCES INC - LICENSEE WILL PAY CO LICENSE EXECUTION FEE,DEVELOPMENT, SALES MILESTONES UP TO $61 MILLION, AND ROYALTIES ON ALL FUTURE SALES   * ENVERIC BIOSCIENCES INC - LICENSEE ALSO HAS A CASH BUYOUT OPTIONSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433417877","title":"Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids","url":"https://stock-news.laohu8.com/highlight/detail?id=2433417877","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433417877?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:00","pubTimestamp":1715166000,"startTime":"0","endTime":"0","summary":"Biotechnology licensee expected to progress methods targeting breast and other cancers using cannabinoids in combination with chemotherapeutic drugs. CAMBRIDGE, Mass., May 08, 2024----Enveric Biosciences, Inc , a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company  to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers for development through additional discovery and preclinical stages using cannabinoids in combination with chemotherapeutic drugs to treat cancer.\"We are excited to see the Licensee taking this innovative approach in effort to advance a novel treatment based on our discovery,\" said Joseph Tucker, Ph.D., Director and CEO of Enveric. \"We look forward to partnering with the L","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/r_RE7qFKizSh_c9CxIgRlw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0ea2d460440b3c55ea30f69cf9e228ac","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/r_RE7qFKizSh_c9CxIgRlw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0ea2d460440b3c55ea30f69cf9e228ac"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enveric-biosciences-announces-signing-non-110000958.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428346910","title":"New Strong Buy Stocks for April 17th","url":"https://stock-news.laohu8.com/highlight/detail?id=2428346910","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428346910?lang=en_us&edition=fundamental","pubTime":"2024-04-17 19:26","pubTimestamp":1713353160,"startTime":"0","endTime":"0","summary":"Here are five stocks added to the Zacks Rank #1  List today:. Byrna Technologies Inc. BYRN: This non-lethal defense technology companyhas seen the Zacks Consensus Estimate for its current year earnings increasing 157.1% over the last 60 days.Byrna Technologies Inc. price-consensus-chart | Byrna Technologies Inc. Quote. Y-mAbs Therapeutics, Inc. YMAB: This commercial-stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 42.7% over the last 60 days.Y-mAbs Therapeutics, Inc. price-consensus-chart | Y-mAbs Therapeutics, Inc. Quote. Sandstorm Gold Ltd. SAND: This gold royalty company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.Sandstorm Gold Ltd price-consensus-chart | Sandstorm Gold Ltd Quote. Corcept Therapeutics Incorporated price-consensus-chart | Corcept Therapeutics Incorporated Quote. Enveric Biosciences, Inc. ENVB: This biotechnology company has seen the Zacks Cons","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-buy-stocks-april-17th-112600259.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426784617","title":"New Strong Buy Stocks for April 12th","url":"https://stock-news.laohu8.com/highlight/detail?id=2426784617","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2426784617?lang=en_us&edition=fundamental","pubTime":"2024-04-12 19:29","pubTimestamp":1712921340,"startTime":"0","endTime":"0","summary":"Here are five stocks added to the Zacks Rank #1  List today:. Zuora, Inc. ZUO: This enterprise software company that creates and provides software for businesses to launch and manage their subscription-based services has seen the Zacks Consensus Estimate for its current year earnings increasing 28.1% over the last 60 days.Intrusion Inc. INTZ: This cybersecurity company based in the United States has seen the Zacks Consensus Estimate for its current year earnings increasing 65.6% over the last 60 days.SIGA Technologies, Inc. SIGA: This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.9% over the last 60 days.Siga Technologies Inc. price-consensus-chart | Siga Technologies Inc. Quote. Enveric Biosciences, Inc. ENVB: This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.Enveric Biosciences, Inc. price-consensus-chart | Enveric Biosciences, Inc. Quote. Nort","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rYP8VPOUfQj30jWv52_m5w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/53d9a3fd304ab73d580828e5367313eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rYP8VPOUfQj30jWv52_m5w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/53d9a3fd304ab73d580828e5367313eb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-buy-stocks-april-12th-112900259.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424841372","title":"FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424841372","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424841372?lang=en_us&edition=fundamental","pubTime":"2024-04-03 22:00","pubTimestamp":1712152834,"startTime":"0","endTime":"0","summary":"Gainers: ARCA biopharma  +104%. Kintara Therapeutics  +103%. Vanda Pharmaceuticals  +26%. Addex Therapeutics ADR  +22%. Helius Medical Technologies  +19%.  Losers: Acorda Therapeutics  -20%. Nexalin Technology  -16%. Enveric Biosciences  -15%. FibroGen  -13%. Petros Pharmaceuticals  -9%.  S&P 500 Health Care Sector +0.26% to 1685.56. Health Care Equipment & Services +0.22% to 1939.49. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.29% to 1389.2.  More on Health Care Select Sector SPDR  XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086832-fibrogen-acorda-therapeutics-enveric-biosciences-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424814118","title":"SOL, MESO and ACOR among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424814118","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424814118?lang=en_us&edition=fundamental","pubTime":"2024-04-03 20:12","pubTimestamp":1712146360,"startTime":"0","endTime":"0","summary":"Losers: View VIEW-62%reaches deal with Cantor Fitzgerald and RXR to become a private company.BYND Cannasoft Enterprises  -28%announcesfinancial results for the year ended December 31, 2023.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086702-sol-meso-and-acor-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2423443509","title":"Enveric Biosciences Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2423443509","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2423443509?lang=en_us&edition=fundamental","pubTime":"2024-03-30 05:01","pubTimestamp":1711746074,"startTime":"0","endTime":"0","summary":"* Enveric Biosciences Inc    reported a quarterly adjusted loss of $1.47 per share for the quarter ended in December.  The mean expectation of three analysts for the quarter was for a loss of $1.54 pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422923128","title":"Enveric Biosciences Inc    expected to post a loss of $1.28 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2422923128","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422923128?lang=en_us&edition=fundamental","pubTime":"2024-03-28 04:03","pubTimestamp":1711569795,"startTime":"0","endTime":"0","summary":"* Enveric Biosciences Inc     is expected to report resultson May 13 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate for Enveric Biosciences Inc is for a loss of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422690487","title":"Enveric Biosciences reports Q4 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2422690487","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422690487?lang=en_us&edition=fundamental","pubTime":"2024-03-26 20:43","pubTimestamp":1711456996,"startTime":"0","endTime":"0","summary":"Enveric Biosciences press release  : Q4 Net loss attributable to stockholders was $3.44 million, including $1.48 million in net non-cash expense, with a basic and diluted loss per share of $1.46.More on Enveric Biosciences  Enveric gains on out-licensing deal of new chemical entities for joint disease treatments Enveric stock jumps 13% on pipeline update Seeking Alpha’s Quant Rating on Enveric Biosciences Historical earnings data for Enveric Biosciences Financial information for Enveric Biosciences","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083671-enveric-biosciences-reports-q4-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2422693240","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2422693240","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2422693240?lang=en_us&edition=fundamental","pubTime":"2024-03-26 19:01","pubTimestamp":1711450860,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023. --  Selected neuroplastogen lead candidate EB-003, a potential. important repeat-dose toxicology studies, genotoxicity studies, and key. \"The fourth quarter of 2023 and early 2024 was a significant period for Enveric, highlighted by the selection of EB-003 as our lead development candidate. We believe EB-003 is a groundbreaking, neuroplastogen drug candidate that offers the potential to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based molecules,\" said Joseph Tucker, Ph.D., Director and CEO of Enveric. \"Based on numerous discussions with large pharmaceutical companies, mental health professionals, and leading researchers, we believe it is evident that widespread market acceptance of psychedelic-inspired drugs will ultimately be determined by the ability to administer such medications in an outpatient ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2421017673","title":"BILI, EXAI and ENVB among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2421017673","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421017673?lang=en_us&edition=fundamental","pubTime":"2024-03-21 20:43","pubTimestamp":1711025003,"startTime":"0","endTime":"0","summary":"Losers: Destination XL Group  -16% after Q4 earnings release. Tourmaline Bio  -30%. Apyx Medical Corp  -17% after Q4 earnings release. Five Below  -12% after Q4 earnings release. Designer Brands  -12% after Q4 earnings release. Academy Sports and Outdoors  -12% after Q4 earnings release. Paltalk  -11%. Exscientia Plc  -11% after FY earnings release.  Treasure Global  -11%. Pyxis Oncology  -11% reports financial results for fourth Quarter and full year 2023. InflaRx N.V.  -11% reports FY results. Anghami  -10%. Li Auto  -9% after slashing Q1 delivery target  LexinFintech Holdings Ltd  -8% after Q4 earnings release. Baozun  -7% after Q4 earnings release. Accenture  -7% after Q2 earnings release. Bilibili  -6%. Danimer Scientific  -6% looks to raise $15M in a direct offering. Enveric Biosciences  -6%. TruGolf Holdings  -6%. SCWorx Corp  -5%.   More on Pre-market losers & stocks.  Bilibili Stock Downgraded To Sell After Assessing Q4 Earnings Bilibili Inc.  Q4 2023 Earnings Call Transcript ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4082039-bili-exai-and-envb-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420756682","title":"Enveric Biosciences Shares Pop 20% After Out-Licensing Deals Valued Up to $82M","url":"https://stock-news.laohu8.com/highlight/detail?id=2420756682","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2420756682?lang=en_us&edition=fundamental","pubTime":"2024-03-19 22:46","pubTimestamp":1710859560,"startTime":"0","endTime":"0","summary":"Enveric Biosciences shares popped 20% to $1.32 after news of out-licensing cannabinoid-COX-2 conjugate compounds for pharmaceutical and non-pharmaceutical applications for treatment of joint diseases.The stock is down 28% over the last 12 months.The biotechnology company disclosed it signed two non-binding term sheets with an undisclosed biotechnology company.Enveric said it could receive milestone payments that total up to $82 million through the out-licensing of the two assets and meeting various development and sales milestones.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2420822073","title":"Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2420822073","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420822073?lang=en_us&edition=fundamental","pubTime":"2024-03-19 22:00","pubTimestamp":1710856851,"startTime":"0","endTime":"0","summary":"Gainers: Fusion Pharmaceuticals  +97%. SCWorx  +68%. Enveric Biosciences  +43%. Hoth Therapeutics  +23%. Enliven Therapeutics  +20%.  Losers: Graphite Bio  -13%. Adverum Biotechnologies  -19%. Lantern Pharma  -18%. Acurx Pharmaceuticals  -16%. Eyenovia  -14%.  S&P 500 Health Care Sector -0.02% to 1689.96. Health Care Equipment & Services -0.1% to 1973.91. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.02% to 1378.25.  More on Health Care Select Sector SPDR  XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4081116-graphite-bio-scworx-acurx-pharmaceuticals-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420226167","title":"Enveric gains on out-licensing deal of new chemical entities for joint disease treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2420226167","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420226167?lang=en_us&edition=fundamental","pubTime":"2024-03-19 20:44","pubTimestamp":1710852250,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (NASDAQ:ENVB) has signed two non-binding term sheets with an undisclosed biotechnology company, to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4080997-enveric-stock-gains-on-out-licensing-deal-of-new-chemical-entities-for-joint-disease-treatments","is_publish_highlight":false,"gpt_icon":0},{"id":"2420722516","title":"WW, ATNM and XTIA are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2420722516","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420722516?lang=en_us&edition=fundamental","pubTime":"2024-03-19 20:04","pubTimestamp":1710849858,"startTime":"0","endTime":"0","summary":"Gainers: Fusion Pharmaceuticals  +101% will buy Fusion Pharmaceuticals for ~$2B.  Zoomcar Holdings  +51% partners with Zoomcar to provide pre-booked, on-demand self-drive cars in India.  Enveric Biosciences  +38% Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease.  National Cinemedia  +25% Q4 earnings call release  Spire Global  +18% gains on partnership with NVIDIA to advance AI-driven weather prediction.  Li-Cycle Holdings  +17% gets $75M investment from Glencore.  SCWorx  +18%. Augmedix  +16% Q4 earnings call release  Actinium Pharmaceuticals  +9%. XTI Aerospace  +9%. Atyr Pharma  +8%. Ocugen  +7%. WW International  +7%.   More on premarkets gainers & stock  I Worry That WW International, Formerly Weight Watchers, May Not Survive WW International, Inc.  Q4 2023 Earnings Call Transcript Actinium Pharmaceuticals: Closer To Realizing Its Potential  Oprah expected to endorse","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4080954-ww-atnm-and-xtia-are-among-pre-market-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420242523","title":"BRIEF-Enveric Biosciences Signs Non-Binding Term Sheets To Pursue The Exclusive Out-Licensing Of New Chemical Entities For Pharmaceutical And Non-Pharmaceutical Applications In Joint Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2420242523","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2420242523?lang=en_us&edition=fundamental","pubTime":"2024-03-19 19:14","pubTimestamp":1710846848,"startTime":"0","endTime":"0","summary":"March 19  - Enveric Biosciences Inc   :   * ENVERIC BIOSCIENCES SIGNS NON-BINDING TERM SHEETS TO PURSUE THE EXCLUSIVE OUT-LICENSING OF NEW CHEMICAL ENTITIES FOR PHARMACEUTICAL AND NON-PHARMACEUTICAL APPLICATIONS IN JOINT DISEASE   * ENVERIC COULD POTENTIALLY RECEIVE MILESTONE PAYMENTS THAT TOTAL UP TO APPROXIMATELY $82 MILLION   * ENVERIC - PHARMACEUTICAL APPLICATION TERM SHEET PROVIDES THAT ENVERIC COULD BE ELIGIBLE TO RECEIVE PAYMENTS IN TOTAL UP TO APPROXIMATELY $61 MILLIONSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420242845","title":"Enveric Biosciences Explores Joint Disease Treatment Licensing","url":"https://stock-news.laohu8.com/highlight/detail?id=2420242845","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420242845?lang=en_us&edition=fundamental","pubTime":"2024-03-19 19:12","pubTimestamp":1710846769,"startTime":"0","endTime":"0","summary":"The latest update is out from Enveric Biosciences (ENVB). Enveric Biosciences, Inc. has announced plans to exclusively out-license new chemical ent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enveric-biosciences-explores-joint-disease-treatment-licensing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enveric-biosciences-explores-joint-disease-treatment-licensing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420247348","title":"Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2420247348","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2420247348?lang=en_us&edition=fundamental","pubTime":"2024-03-19 19:00","pubTimestamp":1710846000,"startTime":"0","endTime":"0","summary":"Second biotechnology company to potentially out-license novel compounds from Enveric’s portfolio of assets with possible significant milestone payments and royalties. The pharmaceutical application term sheet provides that Enveric could be eligible to receive future development and sales milestone payments that in total could add up to approximately $61 million, assuming certain conditions are met, including receiving approval for the investigational new drug  application and completing Phases I through III testing of the licensed product. Royalty rates could range from 2.5% up to 10% on future sales, depending on meeting certain sales criteria.The non-pharmaceutical application term sheet provides that Enveric could be eligible to receive future development and sales milestone payments, which in total could add up to approximately $21 million and with royalty rates ranging from 0.25% up to 7%, assuming certain conditions are met, including successful product development and commercial","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sOTxrJJpNdL6YOyv.wOHiA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/de08c09292aa44fd89bb9a77e8f6c0e0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sOTxrJJpNdL6YOyv.wOHiA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/de08c09292aa44fd89bb9a77e8f6c0e0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enveric-biosciences-signs-non-binding-110000523.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418950587","title":"BRIEF-Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered By Non-Binding Term Sheets","url":"https://stock-news.laohu8.com/highlight/detail?id=2418950587","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2418950587?lang=en_us&edition=fundamental","pubTime":"2024-03-12 19:17","pubTimestamp":1710242230,"startTime":"0","endTime":"0","summary":"March 12 (Reuters) - Enveric Biosciences Inc   :   * ENVERIC BIOSCIENCES- ANNOUNCES NEW PATENT ISSUANCES PROTECTING MULTIPLE ASSETS COVERED BY NON-BINDING TERM SHEETSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.enveric.com","stockEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0225},{"period":"3month","weight":0.1943},{"period":"6month","weight":-0.4177},{"period":"1year","weight":-0.4491},{"period":"ytd","weight":-0.2923}],"compareEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0378},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.2599},{"period":"ytd","weight":0.0944}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.110807},{"month":2,"riseRate":0.285714,"avgChangeRate":0.027235},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.1144},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.101116},{"month":5,"riseRate":0.285714,"avgChangeRate":0.140235},{"month":6,"riseRate":0.833333,"avgChangeRate":0.096606},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.063406},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.140506},{"month":9,"riseRate":0.5,"avgChangeRate":-0.055711},{"month":10,"riseRate":0,"avgChangeRate":-0.291213},{"month":11,"riseRate":0.333333,"avgChangeRate":2.480318},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.155958}],"exchange":"NASDAQ","name":"Enveric Biosciences","nameEN":"Enveric Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enveric Biosciences(ENVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enveric Biosciences,ENVB,Enveric Biosciences股票,Enveric Biosciences股票老虎,Enveric Biosciences股票老虎国际,Enveric Biosciences行情,Enveric Biosciences股票行情,Enveric Biosciences股价,Enveric Biosciences股市,Enveric Biosciences股票价格,Enveric Biosciences股票交易,Enveric Biosciences股票购买,Enveric Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enveric Biosciences(ENVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction